Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 7900 E. Union Avenue, Suite 920 DENVER CO 80237 |
Tel: | N/A |
Website: | https://aytubio.com |
IR: | See website |
Key People | ||
Joshua R. Disbrow Chairman of the Board, Chief Executive Officer | Mark K. Oki Chief Financial Officer, Treasurer, Company Secretary | Greg Pyszczymuka Chief Commercial Officer |
Business Overview |
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company's prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions. |
Financial Overview |
For the six months ended 31 December 2023, Aytu Biopharma Inc revenues decreased 17% to $45M. Net loss increased 13% to $8.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects (Loss) gain on derivative warrant liabil decrease from $3.6M (income) to $6.5M (expense), Amortization of intangible assets increase of 9% to $2.6M (expense). |
Employees: | 150 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $12.33M as of Dec 31, 2023 |
Annual revenue (TTM): | $98.50M as of Dec 31, 2023 |
EBITDA (TTM): | $4.50M as of Dec 31, 2023 |
Net annual income (TTM): | -$18.00M as of Dec 31, 2023 |
Free cash flow (TTM): | $6.11M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 5,567,597 as of Feb 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |